Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 17Breast 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 5Breast Cancer Metastatic 2Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Ovarian Neoplasms 1Neoplasm Metastasis 1Her-2 Negative Breast Cancer 1Fludzoparib" and Anti-angiogenic 1Female Breast Cancer Patients 1Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

pembrolizumab 42Paclitaxel 26Cyclophosphamide 25Carboplatin 23olaparib 21Nivolumab 16fludarabine 15Docetaxel 13aldesleukin 12Gemcitabine 11Fulvestrant 11veliparib 9Bevacizumab 9sargramostim 8palbociclib 8durvalumab 8Trastuzumab 8Magnetic Resonance Spectroscopy 8liposomal doxorubicin 7atezolizumab 7Surveys and Questionnaires 7Ipilimumab 7Blood Specimen Collection 7niraparib 6avelumab 6Taxes 6Specimen Handling 6Interleukin-2 6Fluorouracil 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × fluzoparib × Breast × Clear all
NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
98 enrolled
BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡